

Chinese single herbs and active ingredients for postmenopausal osteoporosis: From preclinical evidence to action mechanism

Jing Lin^{1,2,3,§}, Jun Zhu^{4,§}, Yan Wang^{1,2,3}, Na Zhang^{1,2,3}, Hans-Jürgen Gober⁵, Xuemin Qiu^{1,2,3}, Dajin Li^{1,2,3}, Ling Wang^{1,2,3,*}

¹Laboratory for Reproductive Immunology, Hospital & Institute of Obstetrics and Gynecology, Shanghai Medical College, Fudan University, Shanghai, China;

²The Academy of Integrative Medicine of Fudan University, Shanghai, China;

³Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China;

⁴Department of Obstetrics and Gynecology, Wenling People's Hospital, Wenzhou Medical University, Zhejiang, China;

⁵Department of Pharmacy, Kepler University Clinic, Neuromed Campus, Linz, Austria.

Summary

Postmenopausal osteoporosis is a systemic metabolic skeletal disease generally ascribable to a dearth of estrogen. Whether traditional Chinese medicine is effective in management of postmenopausal osteoporosis remains unclear. This article reviews the experimental evidence of both *in vitro* and *in vivo* preclinical studies with the theme of the application of Chinese single herbs and active ingredients in postmenopausal osteoporosis. It includes three single herbs (Herba Epimedium, Rhizoma Drynariae, and Salvia miltiorrhiza) and eight active ingredients (saikosaponins, linarin, echinacoside, sweroside, psoralen, poncirin, vanillic acid, and osthole). The experimental studies indicated their potential use as treatment for postmenopausal osteoporosis and investigated the underlying mechanisms including osteoprotegerin/receptor activator of nuclear factor κ B ligand (OPG/RANKL), extracellular-signal-regulated kinase/c-Jun N terminal kinase/mitogen-activated protein kinase (ERK/JNK/MAPK), estrogen receptor (ER), bone morphogenetic protein (BMP), transforming growth factor (TGF)- β , Wnt/ β -catenin, and Notch signaling pathways. This review contributes to a better understanding of traditional Chinese medicine and provides useful information for the development of more effective anti-osteoporosis drugs.

Keywords: Traditional Chinese medicine (TCM), single herbs, active ingredients, postmenopausal osteoporosis, bone morphogenetic protein (BMP), estrogen receptor (ER)

1. Introduction

Postmenopausal osteoporosis is a systemic metabolic skeletal disease characterized by structural deterioration and high fragility of bone tissue, generally ascribable to a dearth of estrogen. Osteoporosis affects 200 million women worldwide, and the probability of women over 50 affected by an osteoporotic fracture has been estimated to approach one third (1). With an aging population, the

economic burden of osteoporosis increases exponentially. It is often associated with pain and fractures leading to reduced quality of life such as depression, morbidity, and increased mortality, which is considered to be an important public health issue.

Therapeutic agents currently used for osteoporosis include menopausal hormone therapy (MHT), bisphosphonates, calcitonin, selective estrogen receptor modulators (SERMs), parathyroid hormone (PTH) analogs, and so on. However, there have been long-term safety concerns about these drugs. Adverse events in clinical use include increased risk of cardiovascular disease, venous thromboembolism, breast and endometrial cancer, and stroke with hormone therapy; gastrointestinal intolerance, jaw osteonecrosis, atypical femoral fractures, and atrial fibrillation with bisphosphonates; a possible oncogenic association with

[§]These authors contributed equally to this work.

*Address correspondence to:

Dr. Ling Wang, Laboratory for Reproductive Immunology, Hospital & Institute of Obstetrics and Gynecology, Fudan University Shanghai Medical College, 413 Zhaozhou Road, Shanghai 200011, China.

E-mail: Dr.wangling@fudan.edu.cn

salmon calcitonin; lower efficacy on fracture prevention and increased risk of venous thrombotic events with SERMs; nausea, headache, dizziness, hypercalcemia, hypercalciuria with PTH analogs (2). Therefore, safer and more effective alternatives for the management of osteoporosis are being explored.

In recent years, a growing interest has risen in the treatment of postmenopausal osteoporosis with traditional Chinese medicine (TCM). Compared with Western medicine, TCM has fewer adverse events with long-term use, for which extensive experience has been accumulated over thousands of years. Chinese medicinal herbs usually exert their therapeutic effects through a "multi-components, multi-pathways, and multi-targets" mode, which is in accordance with the multifactorial and complicated nature of postmenopausal osteoporosis (3). TCM will be continuously adopted as a cost-effective alternative to chemically synthesized medicines as well as excellent and reliable sources for derivation of natural products for the development of new drugs. A meta-analysis in 2009, which included 14 randomized controlled trials involving 780 patients with postmenopausal osteoporosis, suggested that phytotherapy might possess a similar effect as hormone therapy on bone mineral density (BMD) values with a lower incidence of breast pain and uterine bleeding (4). It was later contradicted by new evidence in 2017 which included 10 randomized controlled trials involving 957 patients and concluded that Chinese herbal medicine alone did not significantly improve lumbar spine BMD (5). Further high-quality clinical trials are required in this field.

In TCM, there is no well-defined disease known as postmenopausal osteoporosis. However, symptom profiles in classical records such as low back pain, fracture, spine deformities, and limb atrophy could be the manifestations of osteoporosis. According to the TCM theoretical extraction of pathogenesis and symptoms, postmenopausal osteoporosis belongs to the TCM syndromes of "Gubi", "Gushi (bone loss)", "Guwei (bone atrophy)", "Guku (lack of bone marrow)", and "Guji (bone polarization)" (6). The role of "kidney" in governing the bone and generating marrow was the starting point to understand TCM, proposed in *Su Wen (Plain Questions)* as early as the Spring and Autumn period and the Warring States (more than 2000 years ago) (7). Therefore, "kidney deficiency" is regarded as the underlying cause of all skeletal pathologies, and Chinese herbal medicine accordingly follows the principle of "tonifying the kidney" to treat both the surface symptoms and internal balance in management of postmenopausal osteoporosis (8). The kidney's role in bone metabolism was later recognized by Western medicine, as it discovered the importance of the kidney in regulating calcium-phosphorus homeostasis, generating active metabolites of Vitamin D, and so on (9). It is noteworthy that the "kidney's role" in Chinese

medicine cannot be equated directly with renal function in Western medicine and the kidney in TCM theory involves the neuro-endocrine and reproductive systems.

2. Single herbs commonly used in postmenopausal osteoporosis

2.1. *Herba Epimedium*

Epimedium brevicornum Maxim is a centuries-old traditional herb. Derived from the dried leaf of *Epimedium brevicornum* Maxim, *Herba Epimedium* (known as YinYangHuo in Chinese) is a popular Chinese traditional herb with a broad range of indications, especially for fatigue, sexual dysfunction, rheumatic diseases, and osteoporosis. To date, over 260 individual constituents have been derived from plants of the *Epimedium* genus, including icariin, icaritin, anhydroicaritin, epimedin, and so on (10). According to TCM theory, *Herba Epimedium* could tonify the kidney and expel dampness, which contributes to strengthening tendons and bones.

2.1.1. Clinical trials

To determine the therapeutic effect of *Herba Epimedium* and to provide clear evidence for clinical practice, Wang *et al.* identified 37 clinical trials using *Herba Epimedium* in co-prescription with other TCM herbs as anti-osteoporotic drugs to address postmenopausal and senile osteoporosis whose overall efficacy (with markedly and moderately symptom improvement) was between 73% and 100% (11). And *Herba Epimedium* contributed 4.1% to 21.7% of relative weight in these therapeutic formulas. However, these studies could be further criticized because few of them met the standards of randomized, double-blind, placebo-controlled or involved adequate sample size and treatment duration.

2.1.2. In vivo findings

In vivo studies found that *Herba Epimedium* extract and its bioactive components could prevent ovariectomized (OVX) induced bone loss in rats, as evidenced by the suppression of BMD descent and the improvement of biomechanical properties and trabecular microarchitecture.

In evaluation of bone turnover biomarkers, *Herba Epimedium* was found to decrease serum alkaline phosphatase (ALP) activity and urinary deoxypyridinoline levels compared to the OVX group (12). Total flavones of *Epimedium* (TFE) inhibited reduction of procollagen type I N-terminal propeptide (PINP), and increased serum osteocalcin and type I collagen in OVX rats (13,14). Icariin, one of the major components of *Herba Epimedium*, decreased activities of serum tartrate-resistant acid phosphatase (TRAP) and

bone alkaline phosphatase (BALP), decreased serum osteocalcin and ALP activity, decreased C-terminal telopeptide of type I collagen (CTX) levels compared with the OVX group (15-17). Flavonoid fraction of Epimedium (FE), ipriflavone, and anhydroicaritin inhibited serum ALP and TRAP in OVX rats (18).

For calcium and phosphate homeostasis, Herba Epimedium decreased urinary calcium excretion and corrected serum calcium (12,19). TFE decreased urinary calcium excretion, lowered the urinary calcium/creatinine and phosphate/creatinine ratio, suppressed PTH elevation, increased bone calcium and phosphorus content and serum calcium compared to OVX group (14). Icaritin corrected the decreased serum calcium and phosphate (15). Anhydroicaritin decreased urinary calcium and D-pyruvate/creatinine ratio while increasing bone calcium and phosphate (20). FE prevented osteoporosis independent of intestinal calcium absorption (21,22).

For neuro-endocrine regulation, Herba Epimedium and icaritin corrected estrogen decrease in OVX rats (15). TFE improved serum estrogen and increased estrogen receptor α (ER α) and ER β mRNA expression of hypothalamus and hippocampus (23). Herba Epimedium and TFE inhibited the mRNA expression of interleukin (IL)-6 induced by OVX (14).

In gene profile, TFE enhanced osteoprotegerin (OPG) mRNA expression, increased OPG/receptor activator of nuclear factor κ B ligand (RANKL) ratio, and recovered expression of runt-related transcription factor 2 (Runx2) compared to the OVX group (13,14). FE increased OPG protein expression and reduced the RANKL protein expression in OVX rats (18). Icaritin increased the mRNA expression ratio of OPG/RANKL, up-regulated mRNA expression of low-density lipoprotein receptor-related protein 6 (Lrp6) receptor, while it down-regulated glycogen synthase kinase-3 β and Runx2, following OVX (24,25). Icaritin was also found to up-regulate expression of bone morphogenetic protein 2 (BMP2), BMP4, Runx2, osteocalcin, Wnt1, and Wnt3a in OPG knockout mice, and increase the expression of the direct target genes of β -catenin signaling such as AXIN2, dickkopf-related protein 1 (DKK1), T cell factor 1 (TCF1), and lymphoid enhancer-binding factor 1 (LEF1) (26). Icaritin administration altered 23 proteins in bone and 8 metabolites in serum, involving bone remodeling, energy metabolism, cytoskeleton, lipid metabolism, mitogen-activated protein kinase (MAPK) signaling, and calcium signaling (17). Icaritin increased levels of osteoblast-related gene expression compared to pretreatment OVX levels and decreased adipocyte and osteoclast-related gene expression towards pretreatment sham levels (27).

2.1.3. *In vitro* findings

In vitro studies showed that Herba Epimedium and its

bioactive components could stimulate the proliferation, differentiation and mineralization of osteoblasts (12,28-40), suppress the adipogenesis of bone marrow-derived mesenchymal stem cells (BMSCs) (41-44), inhibit the proliferation and differentiation of osteoclasts (45-47), and induce apoptosis and cell cycle arrest and suppress bone resorption of osteoclasts (48). In addition, icaritin was found to significantly attenuate oxidative stress and apoptosis and preserve viability and osteogenic potential of osteoblasts exposed to hypoxia, which indicated that its anti-osteoporotic effect might be attributed to its anti-hypoxic activity (49).

Taken together, the following pathways were involved in the osteogenesis effect of Herba Epimedium and its constituents: *i*) activate extracellular-signal-regulated kinase (ERK), p38, c-Jun N terminal kinase (JNK)/MAPK pathways in rat BMSCs (50), *ii*) through ER-mediated ERK and JNK signal activation in MC3T3-E1 osteoblastic cell line (51), *iii*) via activating phosphatidylinositol-3-kinase (PI3K)-protein kinase B (AKT)-endothelial nitric oxide synthase (eNOS)-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) signal pathway in rat BMSCs (36), *iv*) via BMP or Wnt/ β -catenin signaling pathway in human BMSCs (28), rat BMSCs (26), UMR-106 osteoblastic cells, and osteoblasts in neonatal rat calvaria cultures (52), *v*) via BMP2/SMAD4 signal pathway in hFOB 1.19 human osteoblastic cell line (34), *vi*) involve the ER α -Wnt/ β -catenin signaling pathway in rat BMSCs (38), *vii*) through up-regulation of transforming growth factor (TGF)- β 1, BMP2 expression in rabbit BMSCs (30), through up-regulation of BMP2 and Runx2 mRNA expression in calvarial osteoblasts from pups (13), *viii*) via Notch signaling pathway in rat BMSCs (53), *ix*) increase OPG and the OPG/RANKL ratio in UMR-106 osteoblastic cells (12), and *x*) stimulate ER-dependent osteoblastic functions and activate ER in a ligand-independent manner in UMR-106 osteoblastic cells (24,39).

At least three pathways were involved in the inhibition of adipogenesis in rat BMSCs: *i*) reduce peroxisome proliferator-activated receptor γ (PPAR γ) mRNA expression (41), *ii*) down-regulate expression of DKK1 protein (42), and *iii*) activate Wnt/ β -catenin signaling pathway (43).

The following pathways were involved in the anti-resorptive effect of Herba Epimedium and its constituents in co-culture of BMSCs and osteoblasts: *i*) suppress MAPKs/nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) regulated hypoxia inducible factor (HIF)-1 α and prostaglandin E2 (PGE2) synthesis (45), *ii*) inhibit p38 and JNK activation, *iii*) up-regulate expression of OPG while down-regulating RANKL, *iv*) repress the synthesis of cyclooxygenase-2 and PGE2, *v*) inhibit IL-6 and tumor necrosis factor (TNF)- α expression, and *vi*) interact with nuclear ERs via the mitochondrial pathway (48).

2.2. *Rhizoma Drynariae*

The traditional Chinese herb *Rhizoma Drynariae* (Gu-Sui-Bu) is commonly used to manage musculoskeletal traumatic disorders of orthopedics with satisfactory results, as it tonifies the kidney, activates blood circulation, and promotes tissue regeneration. Modern pharmacological studies have revealed more than 300 different constituents in this herb, including flavonoids, triterpenoids, phenylpropanoids, lignans, phenolic acids, and so on (54).

2.2.1. *Clinical findings*

A meta-analysis performed in 2017, which included 6 randomized controlled trials involving 846 patients, showed that both the flavonoids from *Rhizoma Drynariae* and the combined therapy alone were better than conventional treatments in improving BMD value with no severe adverse drug reactions (55). This conclusion needs future research to confirm.

2.2.2. *In vivo preclinical data*

Rhizoma Drynariae had a similar effect compared to estrogen in maintaining normal trabecular structure and connections by inhibiting the increased bone turnover of postmenopausal osteoporosis (56). *Drynariae* total flavonoids could decrease cathepsin K mRNA and increase bending load compared to OVX group (57). *Drynariae* flavonoid fraction exerted dose-dependent effects in improving BMD, bone strength at the femur, tibia and lumbar spine in OVX mice (58). Naringin reversed OVX-induced bone loss *via* increasing BMD, bone volume, trabecular thickness, and mechanical strength (59,60). Naringin up-regulated vascular endothelial growth factor (VEGF) mRNA expression and vascular endothelial growth factor receptor (VEGFR)-2 mRNA and protein expression, which increased the number of vessels, vessel volume, and vessel thickness around the osteoporotic fracture sites (61).

2.2.3. *In vitro preclinical data*

Rhizoma Drynariae and its bioactive constituents were able to promote the osteoblastic proliferation, differentiation, and maturation (56,58,59,62-70), inhibit osteoblastic apoptosis (71), suppress osteoclastogenesis (72-74), promote the apoptosis of osteoclasts (60), stimulate both cellular and humoral immunity (75), and inhibit cathepsins K processing (76,77).

Mechanisms involved in the osteogenesis and osteolysis effect of *Rhizoma Drynariae* and its components included: *i*) promote proliferation, differentiation, and maturation of rat calvarial osteoblasts (64) and UMR-106 osteoblastic cells (58,68) *via* ER pathway, *ii*) promote osteoblastogenesis from rat

BMSCs *via* the Notch signaling pathway (70), *iii*) inhibit osteoclastogenesis of human amniotic fluid-derived stem cells (hAFSCs) *via* elevating OPG/RANKL ratio and induce the osteogenesis of hAFSCs *via* the BMP and Wnt/ β -catenin pathways (72), and *iv*) promote the apoptosis of osteoclasts by regulating the mitochondrial apoptosis pathway using RAW 264.7 cells (60).

2.3. *Salvia miltiorrhiza*

Salvia miltiorrhiza, known as Danshen in Chinese, is one of the best-known Chinese traditional herbs whose root has been clinically exploited in treating postmenopausal syndrome. There are more than 100 compounds isolated from *Salvia miltiorrhiza*, such as tanshinone, salvianic acid, and flavonoids (78). As is recorded in *Qian Jin Fang*, the application of *Salvia miltiorrhiza* for treating blood stasis and injuries dated back over hundreds of years. In TCM, *Salvia miltiorrhiza* has been described to remove blood stasis, promote menstrual blood flow, and reduce pain. It is commonly used in patients with menstrual disorders, blood stasis, and rheumatism.

2.3.1. *Clinical data*

Guo *et al.* reported in 2014 that 25 clinical trials were conducted in which primary osteoporosis was treated with *Salvia miltiorrhiza* plus other herbs with an overall efficacy of 85% to 96% in markedly and moderately symptom improvement (78). Due to the huge variation in trial protocols, the exact therapeutic effects of *Salvia miltiorrhiza* could not be assessed from the available data.

2.3.2. *In vivo preclinical data*

Chae *et al.* demonstrated that the aqueous extracts of *Salvia miltiorrhiza* could enhance bone mechanical strength and prevent trabecular bone resorption in OVX Sprague-Dawley rats (79). Cui *et al.* found that *Salvia miltiorrhiza* prevented OVX-induced bone loss probably due to its anti-oxidative stress and partly *via* modulation of osteoclast maturation and number, because it decreased the osteoclast activation marker TRAP-5b and oxidative stress parameters malondialdehyde (MDA) and NO induced by OVX (80). Individual compound tanshinone also prevented a decrease in trabecular bone volume and trabecular number and an increase in osteoclast surface in vertebra, and partially prevented a decrease in trabecular bone volume and trabecular number in the tibia (81).

2.3.3. *In vitro findings*

Salvia miltiorrhiza increased osteoblast number and inhibited osteoclastogenesis (82). Isolated from *Salvia*

miltiorrhiza Bunge, tanshinone IIA, tanshinone I, cryptotanshinone, 15,16-dihydrotanshinone I, and ferruginol were found to reduce the formation of TRAP positive multinuclear osteoclasts (83). Tanshinol was able to ameliorate the accumulation of reactive oxygen species, decrease in cell viability, cell cycle arrest and apoptosis, and inhibition of osteoblastic differentiation induced by hydrogen peroxide (84). Salvianic acid A increased ALP activity, type I collagen mRNA and OPG mRNA expression, and stimulated nodule mineralization of rat osteoblasts. It stimulated osteogenesis and repressed adipogenesis from BMSCs (85).

Mechanisms involved in the osteogenesis and osteolysis effect of *Salvia miltiorrhiza* and its constituents included: *i*) first down-regulate and then up-regulate OPG/RANKL in MC3T3-E1 osteoblastic cell line (86), *ii*) promote osteogenesis through the ERK signaling pathway in human mesenchymal stem cells (87), *iii*) attenuate oxidative stress *via* down-regulation of forkhead box O3 (FoxO3a) signaling, and rescue the decrease of osteoblastic differentiation through up-regulation of Wnt signal under oxidative stress in pluripotent mesenchymal precursor C2C12 cells and preosteoblastic MC3T3-E1 cells (84), *iv*) inhibit osteoclast formation by inhibiting the expression of c-Fos and nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) induced by RANKL in a rat BMSCs/calvarial osteoblast co-culture system (88), *v*) prevent osteoclast differentiation by inhibiting RANKL expression and NF- κ B induction in co-culture of monocyte-macrophage cell line RAW 264.7 and osteoblast cell line type CRL 12257 (89), and *vi*) reduce the number and activity of osteoclasts *via* suppression of RANK activated AKT, NF- κ B, and MAPKs signal transduction in rat BMSCs/calvarial osteoblasts co-culture system (90).

3. Active ingredients commonly used in postmenopausal osteoporosis

As forms of Chinese herbal medicine, active ingredients of Chinese medicine are isolated from single herbs or traditional herbal formulas and prepared using modern advanced pharmaceutical technology, such as icariin from *Herba Epimedii*, naringin from *Rhizoma Drynariae*, and tanshinone from *Salvia miltiorrhiza*. Compared to traditional decoctions, active ingredients have various dosage forms including injections, tablets, pills, capsules, and liquids. They are safer, more effective, and easier to use. Thus, active ingredients of Chinese medicine become increasingly popular in China and attract worldwide attention.

3.1. Saikosaponins

Radix Bupleuri, made from dried roots of *Bupleurum scorzoniferifolium* Willd., is commonly used in the

prescriptions of traditional Chinese medicine. It has been utilized to treat various discomforts, including influenza, malaria, chronic hepatitis, and menstrual disorders. Saikosaponins, major bioactive compounds isolated from *Radix Bupleuri*, have exhibited anti-inflammatory, antimycotic, and immuno-regulatory pharmacological properties.

Saikosaponin A and saikosaponin D significantly repressed inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 expression, reduced TNF- α and IL-6 production, and inhibited NF- κ B translocation in lipopolysaccharide (LPS)-induced murine macrophage cell line RAW264.7 cells (91). *In vitro* study revealed that saikosaponin A suppressed osteoclastogenesis in C57/BL6 mice bone marrow monocytes and mediated osteoclast differentiation through inhibiting RANKL-induced p38, ERK, JNK, and NF- κ B activation in murine RAW264.7 cell line (92). Saikosaponins showed a potent anti-inflammatory and anti-osteoporotic effect as safe and effective agents for management of postmenopausal osteoporosis.

3.2. Linarin

Flos Chrysanthemi Indici, one of the most important drugs in traditional Chinese medicine, possesses biological properties such as antioxidative, antibacterial, antiviral, and antimycotic effects. Linarin, a natural flavonoid compound in *Flos Chrysanthemi Indici*, has been shown to preserve the trabecular bone microarchitecture of OVX C57/BL6 mice. Linarin enhanced osteoblast differentiation and mineralization in MC3T3 E1 cells, mediated by activating the BMP2/Runx2 pathway *via* protein kinase A (PKA) signaling pathway (93).

3.3. Echinacoside

Echinacoside is one of the major constituents of *Herba Cistanches*, a famous traditional Chinese medicine. As a natural polyphenolic compound, echinacoside possesses effective anti-inflammatory, antioxidative, neuroprotective, hepatoprotective, and vasodilative properties. Administration of echinacoside could effectively and safely prevent bone loss in OVX-induced Sprague-Dawley rats through increasing OPG/RANKL ratio, which revealed its potential of developing into a novel agent for treatment in postmenopausal osteoporotic women (94).

3.4. Sweroside

Fructus Corni has wide application in the clinic with a long history, of which Sweroside is an important constituent. Modern pharmacology shows that sweroside has a variety of pharmacological functions including vasorelaxation, antihepatitis, anti-inflammatory, and




Figure 1. The mechanism of action of Chinese single herbs on pre-osteoblasts. Chinese single herbs interact with at least eight pathways for the treatment of osteoporosis in pre-osteoblasts: *i*) via BMP signaling pathway, *ii*) via Wnt/ β -catenin pathway, *iii*) activate ERK, p38, JNK, MAPK pathways, *iv*) via up-regulation of TGF- β 1 expression, *v*) through ER signal activation, *vi*) activate PI3K-AKT-eNOS-NO-cGMP-PKG signal pathway, *vii*) via Notch signaling pathway, and *viii*) reduce PPAR γ mRNA and DKK1 protein to inhibit adipogenesis. (Abbreviations: HEP, Herba Epimedii; SM, Salvia miltiorrhiza; RD, Rhizoma Drynariae; DKK1, dickkopf-related protein 1; LRP, lipoprotein receptor-related proteins; BMP, bone morphogenetic protein; BMPR, BMP receptor; JNK, c-Jun N terminal kinase; MAPK, mitogen-activated protein kinase; ERK, extracellular-signal-regulated kinase; TGF β , transforming growth factor β ; TGF β R, TGF β receptor; ER, estrogen receptor; ERE, estrogen-response element; PI3K, phosphatidylinositol-3-kinase; AKT, protein kinase B; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; cGMP, cyclic guanosine monophosphate; PKG, protein kinase G; NICD, Notch intracellular domain; PPAR γ , peroxisome proliferator-activated receptor γ .)

antiallergic effects. Sweroside was found to effectively induce proliferation and inhibit apoptosis in human osteosarcoma cell line MG-63 and Wistar rat osteoblastic cells (95), which displayed bright prospects as a therapeutic natural product for osteoporosis.

3.5. Psoralen

Psoralen is extracted from *Psoralea corylifolia*, which is one of the most commonly prescribed herbs for the treatment of bone and joint diseases. Psoralen was found to promote *in vitro* osteoblast differentiation dose-dependently, evidenced by increased ALP activity and enhanced expression of osteoblast-specific marker genes such as type I collagen and osteocalcin. Psoralen might act through the BMP signaling pathway as it could increase the gene expression of BMP2 and BMP4 as well as the protein level of phospho-SMAD1/5/8 (96).

3.6. Poncirin

Poncirin is isolated from *Poncirus trifoliata* and possesses anti-bacterial and anti-inflammatory activities. Studies have showed that poncirin could inhibit adipogenesis and enhance osteoblast differentiation in BMSCs. In C3H10T1/2 mesenchymal stem

cells, poncirin prevented adipocyte differentiation, demonstrated by decreased accumulation of cytoplasm lipid droplets and down-regulated mRNA expression of PPAR- γ and CCAAT-enhancer-binding protein- β (C/EBP- β). In murine BMSCs, poncirin enhanced expression of Runx2, ALP, and osteocalcin, and increased mineral nodule formation (97).

3.7. Vanillic acid

Vanillic acid is a phenolic acid isolated from the bioactive fraction of *Sambucus williamsii* Hance. It stimulated the proliferation and ALP activity in rat osteoblast-like UMR 106 cells, and also increased mRNA expression of genes involved in osteoblast functions and osteoclastogenesis such as Runx2, osteocalcin, and the OPG/RANKL ratio. Its bone protective effects might be mediated through ER and MAPK pathways (98).

3.8. Osthole

Osthole, extracted from *Fructus Cnidii*, was found to notably improve bone microarchitecture, histomorphometric parameters, and biomechanical properties of OVX rats. It could activate Wnt/ β -catenin pathways, up-regulate BMP2 expression, and stimulate




Figure 2. The mechanism of action of Chinese single herbs on pre-osteoclasts. Chinese single herbs interact with at least six pathways in pre-osteoclasts: *i*) up-regulate expression of OPG while down-regulate RANKL, *ii*) suppress MAPKs/NF- κ B regulated HIF-1 α and PGE2 synthesis, *iii*) inhibit p38, JNK, MAPK, ERK pathways, *iv*) inhibit IL-6 and TNF- α expression, *v*) interact with nuclear ERs, and *vi*) down-regulate the mRNA expression levels of bcl-2 and up-regulate Bax, caspase-3 and cytochrome c. (Abbreviations: HEP, Herba Epimedii; RD, Rhizoma Drynariae; SM, Salvia miltiorrhiza; OPG, osteoprotegerin; RANK, receptor activator of nuclear factor κ B; RANKL, RANK ligand; TNF- α , tumor necrosis factor α ; TNFR, TNF receptor; TRAF, TNF receptor-associated factor; NF- κ B, nuclear factor kappa-light-chain-enhancer of activated B cells; JNK, c-Jun N terminal kinase; MAPK, mitogen-activated protein kinase; ERK, extracellular-signal-regulated kinase; HIF-1 α , hypoxia inducible factor 1 α ; COX-2, cyclooxygenase-2; PGE2, prostaglandin E2; NFATc1, nuclear factor of activated T-cells, cytoplasmic 1; ER, estrogen receptor; IL-6, interleukin 6; IL-6R, IL-6 receptor; STAT, signal transducer and activator of transcription; FasL, Fas ligand.)

osteoblast differentiation *in vitro* (99).

4. Conclusion

In conclusion, Chinese herbal medicine substantially influences postmenopausal osteoporosis as a safer and more effective alternative. However, current clinical studies are not well funded to prove their therapeutic efficacy because most of the studies contain a small sample size and short treatment duration, and their clinical parameters and biomarkers for analysis differ from each other. Both *in vivo* and *in vitro* studies reveal the anti-osteoporotic effect of single herbs targeting different pathways in bone metabolism (Figure 1 and Figure 2). Apart from restoring the balance between osteoblasts and osteoclasts, Chinese single herbs have also been shown to inhibit adipocyte differentiation and exert anti-inflammatory, immuno-regulatory, anti-oxidative, and estrogen-like functions. This review should contribute to a better understanding of Chinese single herbs and active ingredients as treatment for postmenopausal osteoporosis and provide useful information for the development of more effective anti-osteoporosis drugs.

Acknowledgements

This work was supported by the National Natural Science Foundation of China No. 31571196 (to L Wang), the Science and Technology Commission of Shanghai Municipality 2015 YIXUEYINGDAO project No. 15401932200 (to L Wang), the FY2008 JSPS Postdoctoral Fellowship for Foreign Researchers P08471 (to L Wang), the National Natural Science Foundation of China No. 30801502 (to L Wang), the Shanghai Pujiang Program No. 11PJ1401900 (to L Wang), Development Project of Shanghai Peak Disciplines-Integrative Medicine No. 20150407.

References

1. Kanis JA. WHO scientific group technical report: Assessment of osteoporosis at the primary health care level. WHO Collaborating Center for Metabolic Bone Diseases, University of Sheffield, UK. 2007.
2. Gallagher JC, Tella SH. Prevention and treatment of postmenopausal osteoporosis. *J Steroid Biochem Mol Biol.* 2014; 142:155-170.
3. An J, Yang H, Zhang Q, Liu CC, Zhao JJ, Zhang LL, Chen B. Natural products for treatment of osteoporosis:

- The effects and mechanisms on promoting osteoblast-mediated bone formation. *Life Sci.* 2016; 147:46-58.
4. Xu M, Qi C, Deng B, Deng PX, Mo CW. Phytotherapy versus hormonal therapy for postmenopausal bone loss: A meta-analysis. *Osteoporos Int.* 2009; 20:519-526.
 5. Jin YX, Wu P, Mao YF, Wang B, Zhang JF, Chen WL, Liu Z, Shi XL. Chinese herbal medicine for osteoporosis: A meta-analysis of randomized controlled trials. *J Clin Densitom.* 2017; doi: 10.1016/j.jocd.2017.07.003.
 6. Gao Z, Lu Y, Jin J, Xu D. Study of osteoporosis treatment principles used historically by ancient physicians in Chinese medicine. *Chin J Integr Med.* 2013; 19:862-868.
 7. Wang SJ, Li Y, Liu H, Liu ZH. Mechanism underlying osteoporosis: Understanding according to theory of traditional Chinese medicine. *World Chin Med.* 2013; 8:1044-1048. (in Chinese)
 8. Shu B, Shi Q, Wang YJ. Shen(Kidney)-tonifying principle for primary osteoporosis: To treat both the disease and the Chinese medicine syndrome. *Chin J Integr Med.* 2015; 21:656-661.
 9. Zhang Y, Papiasian CJ, Deng HW. Alteration of vitamin D metabolic enzyme expression and calcium transporter abundance in kidney involved in type 1 diabetes-induced bone loss. *Osteoporos Int.* 2011; 22:1781-1788.
 10. Ma HP, He XR, Yang Y, Li MX, Hao DJ, Jia ZP. The genus *Epimedium*: An ethnopharmacological and phytochemical review. *J Ethnopharmacol.* 2011; 134:519-541.
 11. Wang LL, Li Y, Guo YB, Ma RF, Fu M, Niu JZ, Gao SH, Zhang DW. Herba *Epimedii*: An ancient Chinese herbal medicine in the prevention and treatment of osteoporosis. *Curr Pharm Des.* 2016; 22:328-349.
 12. Xie F, Wu CF, Lai WP, Yang XJ, Cheung PY, Yao XS, Leung PC, Wong MS. The osteoprotective effect of Herba *epimedii* (HEP) extract *in vivo* and *in vitro*. *Evid-based Compl Alt.* 2005; 2:353-361.
 13. Qian GF, Zhang XZ, Lu LX, Wu XJ, Li SM, Meng J. Regulation of *Cbfa 1* expression by total flavonoids of Herba *Epimedii*. *Endocr J.* 2006; 53:87-94.
 14. Chen WF, Mok SK, Wang XL, Lai KH, Lai WP, Luk HK, Leung PC, Yao XS, Wong MS. Total flavonoid fraction of the Herba *epimedii* extract suppresses urinary calcium excretion and improves bone properties in ovariectomized mice. *Br J Nutr.* 2011; 105:180-189.
 15. Nian H, Ma MH, Nian SS, Xu LL. Antiosteoporotic activity of icariin in ovariectomized rats. *Phytomedicine.* 2009; 16:320-326.
 16. Li GW, Xu Z, Chang SX, Nian H, Wang XY, Qin LD. Icariin prevents ovariectomy-induced bone loss and lowers marrow adipogenesis. *Menopause.* 2014; 21:1007-1016.
 17. Xue L, Jiang Y, Han T, Zhang N, Qin L, Xin H, Zhang Q. Comparative proteomic and metabolomic analysis reveal the antiosteoporotic molecular mechanism of icariin from *Epimedium brevicornu maxim*. *J Ethnopharmacol.* 2016; 192:370-381.
 18. Zhao BJ, Wang J, Song J, Wang CF, Gu JF, Yuan JR, Zhang L, Jiang J, Feng L, Jia XB. Beneficial effects of a flavonoid fraction of Herba *Epimedii* on bone metabolism in ovariectomized rats. *Planta Med.* 2016; 82:322-329.
 19. Nian H, Xu LL, Ma MH, Qin LP, Zheng HC, Zhang QY. Prevention of bone loss by aqueous extract of *Epimedii sagittatum* in an ovariectomized rat model of osteoporosis. *J Chin Integr Med.* 2006; 4:628-633.
 20. Wu MS, Zhao SZ, Ren LZ, Wang R, Bai X, Han HW, Li B. Experimental study on effect of anhydroicaritin phytosomes in preventing and treating bone loss and enhancing bone quality in ovariectomized osteoporosis rats. *China J Chin Materia Medica.* 2013; 38:2163-2168. (in Chinese)
 21. Qin L, Zhang G, Wang XL, Shi YY, Kong YY, Yang XE, Sheng H, Liang BZ, Liang GS, Yao XS. *Epimedium*-derived flavonoids prevent ovariectomy-induced osteoporosis in rats independent of its enhancement in intestinal calcium absorption. *Natl Med J China.* 2008; 88:1772-1777. (in Chinese)
 22. Zhang G, Qin L, Hung WY, Shi YY, Leung PC, Yeung HY, Leung KS. Flavonoids derived from herbal *Epimedium Brevicornum Maxim* prevent OVX-induced osteoporosis in rats independent of its enhancement in intestinal calcium absorption. *Bone.* 2006; 38:818-825.
 23. Wu M, Zhao S, Ren L. Effects of total flavonoids of *Epimedium sagittatum* on the mRNA expression of the estrogen receptor alpha and beta in hypothalamus and hippocampus in ovariectomized rats. *J Cent South Univ (Med Sci).* 2011; 36:15-20.
 24. Mok S, Chen W, Lai W, Leung P, Wang X, Yao X, Wong M. Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. *Br J Pharmacol.* 2010; 159:939-949.
 25. Chen G, Wang C, Wang J, Yin S, Gao H, Xiang LU, Liu H, Xiong Y, Wang P, Zhu X, Yang LI, Zhang R. Antiosteoporotic effect of icariin in ovariectomized rats is mediated *via* the Wnt/beta-catenin pathway. *Exp Ther Med.* 2016; 12:279-287.
 26. Li XF, Xu H, Zhao YJ, Tang DZ, Xu GH, Holz J, Wang J, Cheng SD, Shi Q, Wang YJ. Icariin Augments Bone Formation and Reverses the Phenotypes of Osteoprotegerin-Deficient Mice through the Activation of Wnt/ beta -Catenin-BMP Signaling. *Evid-based Compl Alt.* 2013; 2013:652317.
 27. Peng S, Zhang G, Zhang B, Guo B, He Y, Bakker AJ, Pan X, Zhen W, Hung L, Qin L, Leung W. The beneficial effect of Icariin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats. *Bone.* 2013; 55:230-240.
 28. Zhang JF, Li G, Chan CY, Meng CL, Lin MC, Chen YC, He ML, Leung PC, Kung HF. Flavonoids of Herba *Epimedii* regulate osteogenesis of human mesenchymal stem cells through BMP and Wnt/beta-catenin signaling pathway. *Mol Cell Endocrinol.* 2010; 314:70-74.
 29. Wang R, Luo J, Kong L. An MC3T3-E1 cell line biomembrane extraction and HPLC-ESI-MS (n) method for simultaneous analysis of potential anti-osteoporosis components of *Epimedium koreanum*. *Chromatographia.* 2012; 75:607-615.
 30. Wu H, Zha ZG, Yao P. Experimental study of icariin in inducing bone marrow mesenchymal stem cell differentiation. *Chin J Integr Tradit West Med.* 2010; 30:410-415. (in Chinese)
 31. Ma HP, Ming LG, Ge BF, Zhai YK, Song P, Xian CJ, Chen KM. Icariin is more potent than genistein in promoting osteoblast differentiation and mineralization *in vitro*. *J Cell Biochem.* 2011; 112:916-923.
 32. Xiao Q, Chen A, Guo F. Effects of Icariin on expression of OPN mRNA and type I collagen in rat osteoblasts *in vitro*. *J Huazhong Univ Sci Technolog Med Sci.* 2005; 25:690-692.
 33. Hsieh T, Sheu S, Sun J, Chen M, Liu M. Icariin isolated

- from *Epimedium pubescens* regulates osteoblasts anabolism through BMP-2, SMAD4, and Cbfa1 expression. *Phytomedicine*. 2010; 17:414-423.
34. Liang W, Lin M, Li X, Li C, Gao B, Gan H, Yang Z, Lin X, Liao L, Yang M. Icariin promotes bone formation *via* the BMP-2/Smad4 signal transduction pathway in the hFOB 1.19 human osteoblastic cell line. *Int J Mol Med*. 2012; 30:889-895.
 35. Cao H, Ke Y, Zhang Y, Zhang CJ, Qian W, Zhang GL. Icariin stimulates MC3T3-E1 cell proliferation and differentiation through up-regulation of bone morphogenetic protein-2. *Int J Mol Med*. 2012; 29:435-439.
 36. Zhai Y, Guo X, Ge B, Zhen P, Ma X, Zhou J, Ma H, Xian CJ, Chen K. Icariin stimulates the osteogenic differentiation of rat bone marrow stromal cells *via* activating the PI3K-AKT-eNOS-NO-cGMP-PKG. *BONE*. 2014; 66:189-198.
 37. Chen KM, Ge BF, Ma HP, Liu XY, Bai MH, Wang Y. Icariin, a flavonoid from the herb *Epimedium* enhances the osteogenic differentiation of rat primary bone marrow stromal cells. *Pharmazie*. 2005; 60:939-942.
 38. Wei Q, Zhang J, Hong G, Chen Z, Deng W, He W, Chen MH. Icariin promotes osteogenic differentiation of rat bone marrow stromal cells by activating the ERalpha-Wnt/beta-catenin signaling pathway. *Biomed Pharmacother*. 2016; 84:931-939.
 39. Xiao HH, Fung CY, Mok SK, Wong KC, Ho MX, Wang XL, Yao XS, Wong MS. Flavonoids from *Herba epimedii* selectively activate estrogen receptor alpha (ERalpha) and stimulate ER-dependent osteoblastic functions in UMR-106 cells. *J Steroid Biochem Mol Biol*. 2014; 143:141-51.
 40. Liu M, Xu H, Ma Y, Cheng J, Hua Z, Huang G. Osteoblasts proliferation and differentiation stimulating activities of the main components of *epimedii folium*. *Pharmacogn Mag*. 2017; 13:90-94.
 41. Liu HQ, Qin JJ, Wu Q. Effect of herb *epimedii* on expression of PPAR gamma mRNA of MSCs during adipogenesis in postmenopausal osteoporosis rats. *Tradit Chin Drug Res Clin Pharm*. 2013; 24:382-385. (in Chinese)
 42. Xu YX, Xu B, Wu CL, Wu Y, Tong PJ, Xiao LW. Dynamic expression of DKK1 protein in the process whereby *Epimedium*-derived flavonoids up-regulate osteogenic and down-regulate adipogenic differentiation of bone marrow stromal cells in ovariectomized rats. *Orthop Surg*. 2011; 3:119-126.
 43. Xu YX, Wu CL, Wu Y, Tong PJ, Jin HT, Yu NZ, Xiao LW. *Epimedium*-derived flavonoids modulate the balance between osteogenic differentiation and adipogenic differentiation in bone marrow stromal cells of ovariectomized rats *via* Wnt/beta-catenin signal pathway activation. *Chin J Integr Med*. 2012; 18:909-917.
 44. Zhang S, Feng P, Mo G, Li D, Li Y, Mo L, Yang Z, Liang. Icariin influences adipogenic differentiation of stem cells affected by osteoblast-osteoclast co-culture and clinical research adipogenic. *Biomed Pharmacother*. 2017; 88:436-442.
 45. Hsieh T, Sheu S, Sun J, Chen M. Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-kappa B regulated HIF-1 alpha and PGE2 synthesis. *Phytomedicine*. 2011; 18:176-185.
 46. Zhang JF, Li G, Meng CL, Dong Q, Chan CY, He ML, Leung PC, Zhang YO, Kung HF. Total flavonoids of *Herba Epimedii* improves osteogenesis and inhibits osteoclastogenesis of human mesenchymal stem cells. *Phytomedicine*. 2009; 16:521-529.
 47. Liu YQ, Yang QX, Cheng MC, Xiao HB. Synergistic inhibitory effect of Icariside II with Icaritin from *Herba Epimedii* on pre-osteoclastic RAW264.7 cell growth. *Phytomedicine*. 2014; 21:1633-1637.
 48. Zhang D, Zhang J, Fong C, Yao X, Yang M. *Herba epimedii* flavonoids suppress osteoclastic differentiation and bone resorption by inducing G2/M arrest and apoptosis. *Biochimie*. 2012; 94:2514-2522.
 49. Ma HP, Ma XN, Ge BF, Zhen P, Zhou J, Gao YH, Xian CJ, Chen KM. Icariin attenuates hypoxia-induced oxidative stress and apoptosis in osteoblasts and preserves their osteogenic differentiation potential *in vitro*. *Cell Prolif*. 2014; 47:527-539.
 50. Wu Y, Xia L, Zhou Y, Xu Y, Jiang X. Icariin induces osteogenic differentiation of bone mesenchymal stem cells in a MAPK-dependent manner. *Cell Prolif*. 2015; 48:375-384.
 51. Song LG, Zhao JS, Zhang XZ, Li H, Zhou Y. Icariin induces osteoblast proliferation, differentiation and mineralization through estrogen receptor-mediated ERK and JNK signal activation. *Eur J Pharmacol*. 2013; 714:15-22.
 52. Li M, Zhang ND, Wang Y, Han T, Jiang YP, Rahman K, Qin LP, Xin HL, Zhang QY. Coordinate regulatory osteogenesis effects of icariin, timosaponin B II and ferulic acid from traditional Chinese medicine formulas on UMR-106 osteoblastic cells and osteoblasts in neonatal rat calvaria cultures. *J Ethnopharmacol*. 2016; 185:120-131.
 53. Bian Q, Huang JH, Liu SF, Ning Y, Yang Z, Zhao YJ, Shen ZY, Wang YJ. Different molecular targets of icariin on bMSCs in CORT and OVX-rats. *Front Biosci (Elite Ed)*. 2012; 4:1224-1236.
 54. Qiao X, Lin XH, Liang YH, Dong J, Guo DA, Ye M. Comprehensive chemical analysis of the rhizomes of *Drynaria fortunei* by orthogonal pre-separation and liquid chromatography mass spectrometry. *Planta Med*. 2014; 80:330-336.
 55. Zhang YL, Jiang JJ, Shen H, Chai Y, Wei X, Xie YM. Total flavonoids from *Rhizoma Drynariae* (Gusuibu) for treating osteoporotic fractures: Implication in clinical practice. *Drug Des Devel Ther*. 2017; 11:1881-1890.
 56. Wang XL, Wang NL, Zhang Y, Gao H, Pang WY, Wong MS, Zhang G, Qin L, Yao XS. Effects of eleven flavonoids from the osteoprotective fraction of *Drynaria fortunei* (KUNZE) J. SM. on osteoblastic proliferation using an osteoblast-like cell line. *Chem Pharm Bull (Tokyo)*. 2008; 56:46-51.
 57. He WT, Zhou JX, Ding XH, Wang HF, Liang B. Experimental study of *drynaria fortunei* J. SM for the prevention of postmenopausal osteoporosis. *Chin J Osteoporos*. 2012; 444-446+457. (in Chinese)
 58. Wong KC, Pang WY, Wang XL, Mok SK, Lai WP, Chow HK, Leung PC, Yao XS, Wong MS. *Drynaria fortunei*-derived total flavonoid fraction and isolated compounds exert oestrogen-like protective effects in bone. *Br J Nutr*. 2013; 110:475-485.
 59. Li N, Jiang Y, Wooley PH, Xu Z, Yang SY. Naringin promotes osteoblast differentiation and effectively reverses ovariectomy-associated osteoporosis. *J Orthop Sci*. 2013; 18:478-485.
 60. Li F, Sun X, Ma J, Ma X, Zhao B, Zhang Y, Tian P, Li Y, Han Z. Naringin prevents ovariectomy-induced osteoporosis and promotes osteoclasts apoptosis through

- the mitochondria-mediated apoptosis pathway. *Biochem Biophys Res Commun.* 2014; 452:629-635.
61. Song N, Zhao Z, Ma X, Sun X, Ma J, Li F, Sun L, Lv J. Naringin promotes fracture healing through stimulation of angiogenesis by regulating the VEGF/VEGFR-2 signaling pathway in osteoporotic rats. *Chem Biol Interact.* 2017; 261:11-17.
 62. Jeong J, Lee J, Yoon C, Kim H, Kim C. Drynariae Rhizoma promotes osteoblast differentiation and mineralization in MC3T3-E1 cells through regulation of bone morphogenetic protein-2, alkaline phosphatase, type I collagen and collagenase-1. *Toxicol in Vitro.* 2004; 18:829-834.
 63. Jeong JC, Lee JW, Yoon CH, Lee YC, Chung KH, Kim MG, Kim CH. Stimulative effects of Drynariae Rhizoma extracts on the proliferation and differentiation of osteoblastic MC3T3-E1 cells. *J Ethnopharmacol.* 2005; 96:489-495.
 64. Zhai YK, Niu YB, Pan YL, Li CR, Wu XL, Mei QB. Effects of naringin on proliferation, differentiation and maturation of rat calvarial osteoblasts *in vitro*. *China J Chin Materia Medica.* 2013; 38:105-111. (in Chinese)
 65. Zhang P, Dai KR, Yan SG, Yan WQ, Zhang C, Chen DQ, Xu B, Xu ZW. Effects of naringin on the proliferation and osteogenic differentiation of human bone mesenchymal stem cells. *Eur J Pharmacol.* 2009; 607:1-5.
 66. Chen L, Lei L, Ding P, Tang Q, Wu Y. Osteogenic effect of Drynariae rhizoma extracts and Naringin on MC3T3-E1 cells and an induced rat alveolar bone resorption model. *Arch Oral Biol.* 2011; 56:1655-1662.
 67. Chang EJ, Lee WJ, Cho SH, Choi SW. Proliferative effects of flavan-3-ols and propylgallin derivatives from rhizomes of *Drynaria fortunei* on MCF-7 and osteoblastic cells. *Arch Pharm Res.* 2003; 26:620-630.
 68. Wang X, Zhen L, Zhang G, Wong MS, Qin L, Yao X. Osteogenic effects of flavonoid aglycones from an osteoprotective fraction of *Drynaria fortunei*--an *in vitro* efficacy study. *Phytomedicine.* 2011; 18:868-872.
 69. Li L, Zeng Z, Cai G. Comparison of neoeriocitrin and naringin on proliferation and osteogenic differentiation in MC3T3-E1. *Phytomedicine.* 2011; 18:985-989.
 70. Yu GY, Zheng GZ, Chang B, Hu QX, Lin FX, Liu DZ, Wu CC, Du SX, Li XD. Naringin stimulates osteogenic differentiation of rat bone marrow stromal cells *via* activation of the Notch signaling pathway. *Stem Cells Int.* 2016; 2016:7130653.
 71. Huang ZM, Ouyang GL, Xiao LB, Li NL, Gao HL, He Y, Huang Z, Huang XX. Effects of *Drynaria* total flavonoids on apoptosis of osteoblasts mediated by tumor necrosis factor- α . *J Chin Integr Med.* 2011; 9:173-178. (in Chinese)
 72. Liu M, Li Y, Yang S. Effects of naringin on the proliferation and osteogenic differentiation of human amniotic fluid-derived stem cells. *J Tissue Eng Regen Med.* 2017; 11:276-284.
 73. Qiu ZC, Dong XL, Dai Y, Xiao GK, Wang XL, Wong KC, Wong MS, Yao XS. Discovery of a new class of Cathepsin K inhibitors in Rhizoma *Drynariae* as potential candidates for the treatment of osteoporosis. *Int J Mol Sci.* 2016; 17:2116-2134.
 74. Sun J, Dong G, Lin C, Sheu S, Lin F, Chen L, Chang WH, Wang Y. The effect of Gu-Sui-Bu (*Drynaria fortunei* J. Sm) immobilized modified calcium hydrogenphosphate on bone cell activities. *Biomaterials.* 2003; 24:873-882.
 75. Jeong J, Lee B, Yoon C, Kim H, Kim C. Effects of *Drynariae* rhizoma on the proliferation of human bone cells and immunomodulatory activity. *Pharmacol Res.* 2005; 51:125-136.
 76. Jeong J, Kang S, Youn C, Jeong C, Kim H, Lee Y, Chang Y, Kim C. Inhibition of *Drynariae* Rhizoma extracts on bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts. *Int Immunopharmacol.* 2003; 3:1685-1697.
 77. Jeong JC, Yoon CH, Jeong CW, Lee YC, Chang YC, Kim CH. Inhibitory activity of *Drynariae* rhizoma extracts on cathepsin having bone resorption activity. *Immunopharmacol Immunotoxicol.* 2004; 26:373-385.
 78. Guo YB, Li Y, Xue LM, Severino RP, Gao SH, Niu JZ, Qin LP, Zhang DW, Brömme D. *Salvia miltiorrhiza*: An ancient Chinese herbal medicine as a source for anti-osteoporotic drugs. *J Ethnopharmacol.* 2014; 155:1401-1416.
 79. Chae HJ, Chae SW, Yun DH, Keum KS, Yoo SK, Kim HR. Prevention of bone loss in ovariectomized rats: The effect of *Salvia miltiorrhiza* extracts. *Immunopharm Immunot.* 2004; 26:135-144.
 80. Cui Y, Bhandary B, Marahatta A, Lee GH, Li B, Kim DS, Chae SW, Kim HR, Chae HJ. Characterization of *Salvia Miltiorrhiza* ethanol extract as an anti-osteoporotic agent. *BMC Complement Altern Med.* 2011; 11:120-130.
 81. Cui L, Wu T, Liu YY, Deng YF, Ai CM, Chen HQ. Tanshinone prevents cancellous bone loss induced by ovariectomy in rats. *Acta Pharmacol Sin.* 2004; 25:678-684.
 82. Kim HK, Woo ER, Lee HW, Park HR, Kim HN, Jung YK, Choi JY, Chae SW, Kim HR, Chae HJ. The correlation of *Salvia miltiorrhiza* extract-induced regulation of osteoclastogenesis with the amount of components tanshinone I, tanshinone IIA, cryptotanshinone, and dihydrotanshinone. *Immunopharm Immunot.* 2008; 30:347-364.
 83. Lee SY, Choi DY, Woo ER. Inhibition of osteoclast differentiation by tanshinones from the root of *Salvia miltiorrhiza* Bunge. *Arch Pharm Res.* 2005; 28:909-913.
 84. Yang Y, Su Y, Wang D, Chen Y, Wu T, Li G, Sun X, Cui L. Tanshinol attenuates the deleterious effects of oxidative stress on osteoblastic differentiation *via* Wnt/FoxO3a signaling. *Oxid Med Cell Longev.* 2013; 2013:351895.
 85. Cui L, Liu YY, Wu T, Ai CM, Chen HQ. Osteogenic effects of D+beta-3,4-dihydroxyphenyl lactic acid (salvianic acid A, SAA) on osteoblasts and bone marrow stromal cells of intact and prednisone-treated rats. *Acta Pharmacol Sin.* 2009; 30:321-332.
 86. Chin A, Yang YQ, Chai L, Wong RWK, Rabie ABM. Effects of medicinal herb *Salvia Miltiorrhiza* on osteoblastic cells *in vitro*. *J Orthop Res.* 2011; 29:1059-1063.
 87. Xu D, Xu L, Zhou C, Lee WY, Wu T, Cui L, Li G. Salvianolic acid B promotes osteogenesis of human mesenchymal stem cells through activating ERK signaling pathway. *Int J Biochem Cell Biol.* 2014; 51:1-9.
 88. Lee S. Tanshinone IIA inhibits osteoclast differentiation through down-regulation of c-Fos and NFATc1. *Exp Mol Med.* 2006; 38:256-264.
 89. Nicolin V, Dal Piaz F, Nori SL, Narducci P, De Tommasi N. Inhibition of bone resorption by Tanshinone VI isolated from *Salvia miltiorrhiza* Bunge. *Eur J Histochem.* 2010; 54:e21.
 90. Kim HH, Kim JH, Kwak HB, Huang H, Han SH, Ha H, Lee SW, Woo ER, Lee ZH. Inhibition of osteoclast

- differentiation and bone resorption by tanshinone IIA isolated from *Salvia miltiorrhiza* Bunge. *Biochem Pharmacol.* 2004; 67:1647-1656.
91. Lu CN, Yuan ZG, Zhang XL, Yan R, Zhao YQ, Liao M, Chen JX. Saikosaponin a and its epimer saikosaponin d exhibit anti-inflammatory activity by suppressing activation of NF-kappaB signaling pathway. *Int Immunopharmacol.* 2012; 14:121-126.
92. Zhou C, Liu WG, He W, Wang HB, Chen QQ, Song HP. Saikosaponin a inhibits RANKL-induced osteoclastogenesis by suppressing NF-kappaB and MAPK pathways. *Int Immunopharmacol.* 2015; 25:49-54.
93. Li J, Hao LY, Wu JH, Zhang JQ, Su JS. Linarin promotes osteogenic differentiation by activating the BMP-2/RUNX2 pathway *via* protein kinase A signaling. *Int J Mol Med.* 2016; 37:901-910.
94. Yang XL, Li F, Yang YN, Shen JY, Zou R, Zhu PP, Zhang CF, Yang ZL, Li P. Efficacy and safety of echinacoside in a rat osteopenia model. *Evid Based Complement Alternat Med.* 2013; 2013:926928.
95. Sun H, Li LJ, Zhang AH, Zhang N, Lv HT, Sun WJ, Wang XJ. Protective effects of sweroside on human MG-63 cells and rat osteoblasts. *Fitoterapia.* 2013; 84:174-179.
96. Tang DZ, Yang F, Yang Z, Huang J, Shi Q, Chen D, Wang YJ. Psoralen stimulates osteoblast differentiation through activation of BMP signaling. *Biochem Biophys Res Commun.* 2011; 405:256-261.
97. Yoon HY, Yun SI, Kim BY, Jin Q, Woo ER, Jeong SY, Chung YS. Poncirin promotes osteoblast differentiation but inhibits adipocyte differentiation in mesenchymal stem cells. *Eur J Pharmacol.* 2011; 664:54-59.
98. Xiao HH, Gao QG, Zhang Y, Wong KC, Dai Y, Yao XS, Wong MS. Vanillic acid exerts oestrogen-like activities in osteoblast-like UMR 106 cells through MAP kinase (MEK/ERK)-mediated ER signaling pathway. *J Steroid Biochem Mol Biol.* 2014; 144:382-391.
99. Tang DZ, Hou W, Zhou Q, Zhang M, Holz J, Sheu TJ, Li TF, Cheng SD, Shi Q, Harris SE, Chen D, Wang YJ. Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. *J Bone Miner Res.* 2010; 25:1234-1245.

(Received September 5, 2017; Revised October 18, 2017; Accepted October 23, 2017)